Ovid Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ovid Therapeutics (OVID).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingOutperform# Analysts10Avg. Consensus PT$5Upside to Avg. PT+101.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Guggenheim	Delma Caiati	Initiate	Buy	$7
Oct 5, 2026	Guggenheim	Delma Caiati	Initiate	Buy	$7
Sep 11, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$4→$5
Aug 3, 2026	Oppenheimer	Kostas Biliouris	PT Raise	Outperform	$7→$9
Apr 15, 2026	Wedbush	Laura Chico	Maintained	Outperform	$7
Apr 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$2→$4
Mar 26, 2026	BTIG	Thomas Shrader	Maintained	Buy	$4
Mar 20, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$5→$7
Dec 22, 2025	LifeSci Capital	—	Initiate	Outperform	$4
Dec 22, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$2
Dec 11, 2025	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$3
Nov 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$2→$2
Nov 17, 2025	Leerink Partners	Marc Goodman	Initiate	Outperform	$5
May 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$2→$2
Mar 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$3→$2
Mar 24, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$5→$4
Mar 12, 2025	Wedbush	Laura Chico	PT Cut	Outperform	$4→$3
Jan 29, 2025	Oppenheimer	Francois Brisebois	Upgrade	Perform→Outperform	$4
Dec 4, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3
Sep 30, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

Wedbush analyst Laura Chico reiterates Ovid Therapeutics (NASDAQ:OVID) with a Outperform and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $2 to $4.

Benzinga Newsdesk

Ovid Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ovid Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

People Also Watch

People Also Watch

Ovid Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ovid Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PROGuggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PROHC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PROOppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PROWedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4

People Also Watch

People Also Watch

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $5

PRO
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

PRO
Wedbush Reiterates Outperform on Ovid Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $4